Contrive Datum Insights has published "Man's Multivitamins Supplements Market Size, Share & Industry Analysis, By Form (Tablets, Capsules & Softgels, Gummies, Powders & Others), Age group (Below 30, 30-50, Above 50), Formulation (Synthetic, Natural/Organic), Distribution channel (Pharmacies & Drugstores, Online/E-commerce, Supermarkets & Hypermarkets, Specialty & Health Stores), Application (General Wellness & Immunity, Heart Health, Energy & Performance, Prostate & Urinary Health), and Regional Forecast, 2026-2034". The study sizes the global man's multivitamins supplements market at USD 20.5 billion in 2025 and projects growth from USD 22 billion in 2026 to USD 43.98 billion by 2034, a compound annual growth rate of 9.05% across the forecast period.
Men's multivitamin supplements are tablets, capsules, softgels, gummies and powder formulations that combine multiple vitamins and minerals in a single product, positioned and marketed specifically for adult male consumers rather than as a unisex or family product. Buyers range from younger men seeking general wellness and immune support to older men choosing formulas addressing heart, prostate or energy-related needs, and purchases occur through pharmacies, mass retail, specialty health stores and online direct-to-consumer channels.
Rising preventive health awareness among men
Rising preventive health awareness among men is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 9.05% a year, the form lines exposed to it move fastest: Gummies compounds at 13.53%, taking its share of revenue from 20% to 29% and its value from USD 4.1 billion to USD 12.75 billion.
The study also runs a bull case: the bull case assumes faster e-commerce and subscription adoption alongside quicker uptake of age-specific and condition-specific formulas, sustaining higher average selling prices than the base case. That path ends 2034 at USD 48.38 billion, above the USD 43.98 billion base case.
Against that, the bear case assumes deeper private label price erosion and slower conversion of general wellness buyers into higher priced targeted formulas, compressing both volume growth and average selling price. On that reading 2034 revenue stops at USD 39.58 billion. The weight of the problem sits in Tablets: 38% of 2025 revenue growing at 6.19%, well under the market's 9.05%.
Other Findings in the Study
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Age group | 30-50 | 46% · USD 9.43 billion | Above 50 10.28% |
| Formulation | Synthetic | 58% · USD 11.89 billion | Natural/Organic 11.47% |
| Distribution channel | Online/E-commerce | 34% · USD 6.97 billion | — |
| Application | General Wellness & Immunity | 40% · USD 8.2 billion | Prostate & Urinary Health 13.88% |
- North America was the largest region in 2025, holding 34% of global revenue at USD 6.97 billion and reaching USD 13.19 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 28% in 2025 to 33% in 2034, with revenue growing from USD 5.74 billion to USD 14.51 billion.
- Middle East and Africa remains the smallest region throughout, at 6% of 2025 revenue and 6% by 2034.
- By form, the largest line in 2025 was Tablets, at 38% of revenue and USD 7.79 billion.
- The fastest form line is Gummies, forecast to compound at 13.53% through the period.
- The United States is the largest single country market at USD 5.72 billion in 2025, 27.9% of global revenue.
Every year from 2020 to 2034 is reported, with revenue and growth for each line across five axes: by form, and by age group, formulation, distribution channel and application. The headline total carries bear, base and bull cases at USD 39.58 billion and USD 48.38 billion by 2034. The study also breaks out all five regions to country level, sets out the competitive landscape, and documents the method behind every estimate. Available as a PDF, with a free sample on request.